Lotus Pharmaceuticals, Inc.
LTUS · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | -0.17% | -0.09% | -0.06% |
| EV / EBITDA | 0.00 | -614.91 | -1,280.95 | -1,643.46 |
| Quality | ||||
| ROIC | 0.00% | -331.10% | -457.62% | -396.48% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.02 | 1.13 | 1.00 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | 19.67% | 21.68% | -384.05% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -6.10 | -4.53 | -2.23 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |